U.S. Cell and Gene Therapy Clinical Trials Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The U.S. Cell and Gene Therapy Clinical Trials market is estimated to be valued at USD 15.8 billion in 2025 and is expected to reach USD 38.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.7% from 2025 to 2032. This significant growth highlights the increasing investment and advancements in innovative therapies aimed at treating genetic and rare diseases, reflecting the expanding scope and adoption of cell and gene therapy clinical trials across the U.S.

The market trend is driven by breakthroughs in gene editing technologies such as CRISPR and the growing number of clinical trials targeting cancer, rare genetic disorders, and autoimmune diseases. Additionally, collaborations between biotech firms and academic institutions, along with increasing regulatory support, are accelerating product development and commercialization. There is also a rising focus on personalized medicine, which is fueling demand for tailored cell and gene therapies, thereby propelling robust growth in clinical trial activities in this sector.

Segmental Analysis:

By Therapy Type: Dominance of Gene Therapy Driven by Scientific Advancements and Therapeutic Potential

In terms of By Therapy Type, Gene Therapy contributes the highest share of the U.S. cell and gene therapy clinical trials market owing to its groundbreaking potential to address the root causes of genetic disorders and complex diseases. Gene therapy involves the introduction, removal, or alteration of genetic material within a patient's cells to treat or prevent disease, which opens new avenues for treating previously incurable conditions. The significant advancements in vector design, especially the refinement of viral vectors like adeno-associated viruses (AAV), have enhanced the safety and efficiency of gene delivery, spurring increased clinical trial activity. Additionally, the regulatory environment has become increasingly supportive, with streamlined pathways and designations such as orphan drug status facilitating expedited development for rare genetic conditions. This regulatory support combined with heightened investor interest has catalyzed a surge in gene therapy trials targeting monogenic disorders, some cancers, and metabolic diseases.

Moreover, gene therapy's appeal is amplified by its potential for a one-time curative treatment, contrasting with chronic therapies that require ongoing administration. This capability aligns with growing demands for durable, long-lasting therapeutic solutions across various medical fields. The improved understanding of gene editing technologies like CRISPR-Cas9 has also expanded the scope of gene therapy beyond traditional gene addition techniques, enabling precise correction of genetic mutations. Research institutions, biotechnology startups, and pharmaceutical companies are all actively harnessing these innovations, leading to a robust pipeline and a substantial share of clinical trials focusing on gene therapy. Meanwhile, combined cell-gene therapies and cell therapies are progressing but have comparatively less clinical activity due to the complexities involved in manufacturing and delivery, thus sustaining gene therapy's primacy.

By Phase: Predominance of Phase I Trials Reflecting Innovation and Early-stage Exploration

In terms of By Phase, Phase I clinical trials contribute the highest share of the U.S. cell and gene therapy clinical trials market, as this initial stage represents the critical period of evaluating safety, tolerability, and dosage parameters for novel therapies. The field of cell and gene therapy is intrinsically innovative, with new molecular entities, engineered cells, and gene-editing tools continually emerging, necessitating a substantial investment in early-phase studies. Many therapies are moving into human testing for the first time, which explains the disproportionate volume of Phase I trials compared to later-stage studies.

These Phase I trials are fundamental in establishing proof-of-concept and working to mitigate risks before progressing to expanded patient populations. Furthermore, the complexity of cell and gene therapies often requires meticulous assessment of immune responses, vector biodistribution, and off-target effects, which are primarily addressed during Phase I. The increasing availability of dedicated early-phase clinical trial sites with specialized capabilities in cell and gene therapy manufacturing and administration also facilitates a rise in Phase I studies. Additionally, many private-sector firms and academic institutions initiate Phase I trials to validate novel approaches before seeking partnerships or further investment for late-stage development.

Despite the high attrition rates commonly associated with early-phase studies, the sheer enthusiasm for exploring the therapeutic potential and breaking ground on rare conditions and cancer immunotherapies fuels a consistent pipeline of Phase I trials. Later phases such as Phase II and III, focusing on efficacy and large-scale validation, remain comparatively fewer but crucial, often limited by the stringent criteria and greater resource requirements.

By Application: Oncology as a Primary Driver Fueled by Unmet Needs and Immunotherapy Breakthroughs

In terms of By Application, oncology commands the highest share of U.S. cell and gene therapy clinical trials, primarily propelled by the urgent unmet medical needs across numerous cancer types and the transformative promise of immuno-oncology. Cancer remains one of the leading causes of mortality, prompting intense research efforts to develop novel treatment modalities that can overcome the limitations of conventional therapies like chemotherapy and radiation. Cell and gene therapies, such as CAR-T cell therapies, have demonstrated remarkable efficacy in treating hematologic malignancies, which has boosted clinical trial activity and investor confidence in oncology applications.

This therapeutic domain benefits from significant scientific discovery around tumor antigens, immune checkpoints, and the tumor microenvironment, providing a rich foundation for engineering both gene-modified cells and gene delivery systems to enhance antitumor responses. Moreover, the approval of several revolutionary products within the past decade has validated the clinical applicability of cell and gene therapies in oncology, inspiring an expanding pipeline targeting solid tumors, lymphomas, and other cancer subtypes.

Oncology's dominance is further supported by relatively high funding availability from both public and private sectors, as well as established trial networks that accelerate patient recruitment and data generation. The complexity of cancer biology also necessitates personalized approaches, which cell and gene therapies are uniquely positioned to address. While applications in rare genetic disorders and autoimmune diseases are growing steadily due to advancements in genetic understanding and immunomodulation, oncology's broad patient base and critical need for curative therapies solidify its status as the leading focus area for clinical research activity within the U.S. cell and gene therapy sector.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the U.S. Cell and Gene Therapy Clinical Trials market is driven by a mature biotech ecosystem, robust governmental support, and a concentration of leading pharmaceutical and biotechnology companies. The region's well-established infrastructure for clinical research, including top-tier academic medical centers and Contract Research Organizations (CROs), facilitates rapid trial initiation and execution. Favorable regulatory frameworks from the U.S. Food and Drug Administration (FDA) encourage innovation through programs such as the Regenerative Medicine Advanced Therapy (RMAT) designation, expediting development pathways for promising therapies. The presence of industry giants like Novartis, Gilead Sciences (with its Kite Pharma division), and bluebird bio has also propelled the region's prominence, supported by a strong venture capital environment and collaborations between academia and industry. Trade dynamics further enhance North America's stance, as the U.S. serves both as a hub for global clinical trial conduct and as a key market for advanced cell and gene therapy products.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the Cell and Gene Therapy Clinical Trials market, fueled by expanding healthcare infrastructure, increased governmental investments, and rising patient populations. China, Japan, and South Korea are spearheading this growth, supported by regulatory reforms that streamline clinical trial approvals and encourage innovation. For example, China's National Medical Products Administration (NMPA) has introduced accelerated pathways for regenerative medicine products, while Japan's Pharmaceuticals and Medical Devices Agency (PMDA) offers conditional approvals for regenerative therapies. The region benefits from cost-effective clinical trial execution and an expanding talent pool specialized in biotechnology. Notable companies such as China's Fosun Pharma and Japan's Takara Bio contribute to dynamic developments in the sector. Additionally, international collaborations and technology transfer agreements are becoming more common, enhancing trial quality and innovation in Asia Pacific. Trade policies focusing on improving intellectual property protection and cross-border partnerships also play a critical role in sustaining this rapid advancement.

---

Cell and Gene Therapy Clinical Trials Market Outlook for Key Countries

United States

The United States' market continues to lead innovation and clinical research activity in cell and gene therapies, supported by significant federal funding initiatives such as those from the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA). Major players like Novartis, Gilead Sciences, and Regeneron leverage advanced clinical trial networks to explore a broad range of therapeutic areas, including oncology, rare genetic disorders, and hematology. The strategic collaborations between biotechnology startups and established pharmaceutical firms further enhance the development speed and scope of clinical trials.

China

China's market is rapidly expanding due to strong governmental backing directed at biopharmaceutical innovation, including initiatives under the 14th Five-Year Plan targeting biotechnology leadership. Leading domestic companies, including Fosun Pharma and Legend Biotech, are engaging in multiple clinical trials domestically and globally. Regulatory reforms have expedited trial approvals, and a large patient pool enables quicker recruitment timelines. Furthermore, partnerships with international biotech firms are intensifying, allowing for technology exchange and adoption of global best practices.

Japan

Japan's market benefits from a uniquely supportive regulatory environment that accelerates the development of regenerative medicine through frameworks such as the Act on the Safety of Regenerative Medicine. Companies like Takara Bio and JCR Pharmaceuticals are at the forefront, driving clinical trials in cell therapies for various conditions. The country's strong academic research base, combined with government incentives and a healthcare system receptive to innovative treatments, bolster the clinical trial landscape.

Germany

Germany represents a critical hub within Europe due to its well-developed healthcare system and strong pharmaceutical industry. Companies such as BioNTech and CureVac have notably contributed to advancing gene therapy trials. The European Medicines Agency's (EMA) regulatory structure harmonizes trial conduct across the continent, making Germany a focal point for multi-center clinical studies. Public-private partnerships and government-sponsored innovation clusters further strengthen the region's clinical research infrastructure.

South Korea

South Korea's market has emerged rapidly through strategic government initiatives like the Korean New Deal, which emphasizes biotechnology sector growth. Firms such as Samsung Biologics and SillaJen are key contributors to clinical trial activities, leveraging advanced manufacturing capabilities along with clinical research expertise. The Korean Ministry of Food and Drug Safety (MFDS) has implemented adaptive regulatory approaches to encourage the acceleration of cell and gene therapy trials, enhancing the country's attractiveness as a clinical research destination.

Market Report Scope

Market Segmentation

Therapy Type Insights (Revenue, USD, 2020 - 2032)

• Gene Therapy
• Cell Therapy
• Combined Cell-Gene Therapy
• Others

Phase Insights (Revenue, USD, 2020 - 2032)

• Phase I
• Phase II
• Phase III
• Phase IV
• Others

Application Insights (Revenue, USD, 2020 - 2032)

• Oncology
• Rare Genetic Disorders
• Autoimmune Diseases
• Infectious Diseases
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Bluebird Bio, Inc.
• CRISPR Therapeutics AG
• REGENXBIO Inc.
• Adaptimmune Therapeutics plc
• Sangamo Therapeutics, Inc.
• Kite Pharma, Inc.
• Moderna, Inc.
• Editas Medicine, Inc.
• Intellia Therapeutics, Inc.
• Spark Therapeutics, Inc.
• Audentes Therapeutics, Inc.
• AveXis, Inc.
• Homology Medicines, Inc.
• MeiraGTx Holdings plc
• Fred Hutchinson Cancer Center